Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Debt / NOTE 2.250% 5/1
-
Market price (% of par)
-
153.37%
-
Total 13F principal
-
$500,259,550
-
Principal change
-
-$22,873,500
-
Total reported market value
-
$774,162,021
-
Number of holders
-
56
-
Value change
-
-$20,461,870
-
Number of buys
-
23
-
Number of sells
-
25
Institutional Holders of NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 as of Q4 2019
As of 31 Dec 2019,
NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 was held by
56 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$500,259,550
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, FRANKLIN RESOURCES INC, Invesco Ltd., CALAMOS ADVISORS LLC, BAKER BROS. ADVISORS LP, WELLS FARGO & COMPANY/MN, MACKAY SHIELDS LLC, CNH PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, and LORD, ABBETT & CO. LLC.
This page lists
56
institutional bondholders reporting positions
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.